Luina Bio, one of Australia’s most experienced biopharmaceutical contract development and manufacturing (CDMO) organizations, is expanding to meet the increasing demand in the microbiome and recombinant biopharma markets.   The first stage of the expansion will see Luina open an additional small scale (30L) GMP manufacturing suite in late 2020, broadening he company’s service offering for new clinical projects that need small scale GMP facilities. This facility will be available to customers in ...